{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:53:34Z","timestamp":1786982014968,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Front. Med."],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11684-025-1131-9","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:28:32Z","timestamp":1747114112000},"page":"523-537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation of enzyme activities and genotype with clinical manifestations in Chinese patients of different sexes with classical and late-onset Fabry disease"],"prefix":"10.1007","volume":"19","author":[{"given":"Wenkai","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinggang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"s439","key":"1131_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1651-2227.2002.tb03102.x","volume":"91","author":"H Fabry","year":"2002","unstructured":"Fabry H. Angiokeratoma corporis diffusum\u2014Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy. Acta Paediatr 2002; 91(s439): 3\u20135","journal-title":"Acta Paediatr"},{"issue":"9647","key":"1131_CR2","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet 2008; 372(9647): 1427\u20131435","journal-title":"Lancet"},{"issue":"2","key":"1131_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, West ML, Wanner C, Bichet DG, Christensen EI, Correa-Rotter R, Elliott PM, Feriozzi S, Fogo AB, Germain DP, Hollak CEM, Hopkin RJ, Johnson J, Kantola I, Kopp JB, Kr\u00f6ner J, Linhart A, Martins AM, Matern D, Mehta AB, Mignani R, Najafian B, Narita I, Nicholls K, Obrador GT, Oliveira JP, Pisani A, Politei J, Ramaswami U, Ries M, Terryn W, Tondel C, Torra R, Vujkovac B, Waldek S, Walter J. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int 2017; 91(2): 284\u2013293","journal-title":"Kidney Int"},{"issue":"3","key":"1131_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymanska A, T\u00f8ndel C, Viana-Baptista M, Weidemann F, Hilz MJ. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab 2018; 124(3): 189\u2013203","journal-title":"Mol Genet Metab"},{"issue":"5","key":"1131_CR5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, Elliott PM, Linthorst GE, Wijburg FA, Biegstraaten M, Hollak CE. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol 2017; 28(5): 1631\u20131641","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"1131_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/gim.2016.55","volume":"18","author":"R Schiffmann","year":"2016","unstructured":"Schiffmann R, Fuller M, Clarke LA, Aerts JM. Is it Fabry disease? Genet Med 2016; 18(12): 1181\u20131185","journal-title":"Genet Med"},{"issue":"1","key":"1131_CR7","first-page":"91","volume":"130","author":"M Nowicki","year":"2020","unstructured":"Nowicki M, Bazan-Socha S, Blazejewska-Hyzorek B, Gellert R, Imiela J, Ka\u017amierczak J, Klopotowski M, Oko-Sarnowska Z, Pawlaczyk K, Ponikowski P, Slawek J, Sykut-Cegielska J, Witkowski A, Zwoli\u0144ska D. Enzyme replacement therapy in Fabry disease in Poland: a position statement. Pol Arch Intern Med 2020; 130(1): 91\u201397","journal-title":"Pol Arch Intern Med"},{"issue":"3","key":"1131_CR8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ndt\/gfp554","volume":"25","author":"A Ortiz","year":"2010","unstructured":"Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, Warnock DG. End- stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 2010; 25(3): 769\u2013775","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1131_CR9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 2008; 64(5): 550\u2013555","journal-title":"Pediatr Res"},{"issue":"1","key":"1131_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02186.x","volume":"95","author":"U Ramaswami","year":"2006","unstructured":"Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006; 95(1): 86\u201392","journal-title":"Acta Paediatr"},{"issue":"4","key":"1131_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 2018; 123(4): 416\u2013427","journal-title":"Mol Genet Metab"},{"issue":"12","key":"1131_CR12","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.2215\/CJN.04340510","volume":"5","author":"C Wanner","year":"2010","unstructured":"Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Mardi L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 2010; 5(12): 2220\u20132228","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"1131_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 2009; 11(11): 790\u2013796","journal-title":"Genet Med"},{"issue":"2","key":"1131_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30(2): 184\u2013192","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1131_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow J, Austin HA III, Kopp JB. Natural history of Fabry renal disease: influence of \u03b1-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81(2): 122\u2013138","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1131_CR16","first-page":"189","volume":"64","author":"HM Mahmud","year":"2014","unstructured":"Mahmud HM. Fabry\u2019s disease\u2014a comprehensive review on pathogenesis, diagnosis and treatment. J Pak Med Assoc 2014; 64(2): 189\u2013194","journal-title":"J Pak Med Assoc"},{"key":"1131_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.omtm.2020.08.012","volume":"19","author":"M Lenders","year":"2020","unstructured":"Lenders M, Stappers F, Brand E. In vitro and in vivo amenability to migalastat in Fabry disease. Mol Ther Methods Clin Dev 2020; 19: 24\u201334","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"1131_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP. X-chromosome inactivation in female patients with Fabry disease. Clin Genet 2016; 89(1): 44\u201354","journal-title":"Clin Genet"},{"issue":"21","key":"1131_CR19","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2008.02.050","volume":"51","author":"GE Linthorst","year":"2008","unstructured":"Linthorst GE, Poorthuis BJ, Hollak CE. Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results. J Am Coll Cardiol 2008; 51(21): 2082","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1131_CR20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/jhg.2013.48","volume":"58","author":"T Inoue","year":"2013","unstructured":"Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 2013; 58(8): 548\u2013552","journal-title":"J Hum Genet"},{"issue":"1","key":"1131_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13023-018-0792-8","volume":"13","author":"I Vieitez","year":"2018","unstructured":"Vieitez I, Souto-Rodriguez O, Fernandez-Mosquera L, San Millan B, Teijeira S, Fernandez-Martin J, Martinez-Sanchez F, Aldamiz-Echevarria LJ, Lopez-Rodriguez M, Navarro C, Ortolano S. Fabry disease in the Spanish population: observational study with detection of 77 patients. Orphanet J Rare Dis 2018; 13(1): 52","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1131_CR22","first-page":"70","volume":"19","author":"Y Wu","year":"2018","unstructured":"Wu Y, Xia H, Yuan J, Xu H, Deng X, Liu J, Zhang H, Deng H. Identification of a missense mutation in the \u03b1-galactosidase A gene in a Chinese family with Fabry disease. Curr Genomics 2018; 19(1): 70\u201375","journal-title":"Curr Genomics"},{"issue":"6","key":"1131_CR23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/cge.13936","volume":"99","author":"R Delarosa-Rodr\u00edguez","year":"2021","unstructured":"Delarosa-Rodr\u00edguez R, Santotoribio JD, Paula HA, Gonz\u00e1lez-Meneses A, Garc\u00eda-Morillo S, Jim\u00e9nez-Arriscado P, Guerrero JM, Macher HC. Accuracy diagnosis improvement of Fabry disease from dried blood spots: enzyme activity, lyso-Gb3 accumulation and GLA gene sequencing. Clin Genet 2021; 99(6): 761\u2013771","journal-title":"Clin Genet"},{"issue":"5","key":"1131_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/humu.1219","volume":"18","author":"D Blaydon","year":"2001","unstructured":"Blaydon D, Hill J, Winchester B. Fabry disease: 20 novel GLA mutations in 35 families. Hum Mutat 2001; 18(5): 459","journal-title":"Hum Mutat"},{"issue":"2","key":"1131_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","volume":"34","author":"A Gal","year":"2011","unstructured":"Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease\u2014recommendations of a European expert group. J Inherit Metab Dis 2011; 34(2): 509\u2013514","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"1131_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13023-022-02215-x","volume":"17","author":"F Ezgu","year":"2022","unstructured":"Ezgu F, Alpsoy E, Bicik Bahcebasi Z, Kasapcopur O, Palamar M, Onay H, Ozdemir BH, Topcuoglu MA, Tufekcioglu O. Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective. Orphanet J Rare Dis 2022; 17(1): 90","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"1131_CR27","doi-asserted-by":"publisher","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","volume":"9","author":"J Lukas","year":"2013","unstructured":"Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, Lackner KJ, Meyer W, Wree P, Saviouk V, Rolfs A. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet 2013; 9(8): e1003632","journal-title":"PLoS Genet"},{"issue":"Suppl2","key":"1131_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1023\/A:1012499119196","volume":"24","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R. Natural history of Fabry disease in males: preliminary observations. J Inherit Metab Dis 2001; 24(Suppl 2): 15\u201317","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"1131_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJM199508033330504","volume":"333","author":"S Nakao","year":"1995","unstructured":"Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, Tanaka H. An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333(5): 288\u2013293","journal-title":"N Engl J Med"},{"issue":"3","key":"1131_CR30","doi-asserted-by":"publisher","first-page":"107603","DOI":"10.1016\/j.ymgme.2023.107603","volume":"139","author":"C Wanner","year":"2023","unstructured":"Wanner C, Ortiz A, Wilcox WR, Hopkin RJ, Johnson J, Ponce E, Ebels JT, Batista JL, Maski M, Politei JM, Martins AM, Banikazemi M, Linhart A, Mauer M, Oliveira JP, Weidemann F, Germain DP. Global reach of over 20 years of experience in the patient-centered Fabry Registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community. Mol Genet Metab 2023; 139(3): 107603","journal-title":"Mol Genet Metab"},{"issue":"8","key":"1131_CR31","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/jmg.33.8.682","volume":"33","author":"I Redonnet-Vernhet","year":"1996","unstructured":"Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet 1996; 33(8): 682\u2013688","journal-title":"J Med Genet"},{"issue":"8","key":"1131_CR32","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1136\/jmg.40.8.e103","volume":"40","author":"A Morrone","year":"2003","unstructured":"Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Parini R, Di Rocco M, Feriozzi S, Gabrielli O, Barone R, Pistone G, Spisni C, Ricci R, Zammarchi E. Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J Med Genet 2003; 40(8): e103","journal-title":"J Med Genet"},{"issue":"8","key":"1131_CR33","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","volume":"83","author":"R Dobrovolny","year":"2005","unstructured":"Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC, Elleder M, Karetova D, Pavlikova M, Hrebicek M. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med (Berl) 2005; 83(8): 647\u2013654","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"1131_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/j.1399-0004.2011.01643.x","volume":"80","author":"MG Bouwman","year":"2011","unstructured":"Bouwman MG, Rombach SM, Linthorst GE, Poorthuis BJHM, Lekanne Deprez RH, Aerts JMFG, Wijburg FA. Early cerebral manifestations in a young female with Fabry disease with skewed X-inactivation. Clin Genet 2011; 80(5): 500\u2013502","journal-title":"Clin Genet"},{"key":"1131_CR35","first-page":"100497","volume":"20","author":"MA Hossain","year":"2019","unstructured":"Hossain MA, Wu C, Yanagisawa H, Miyajima T, Akiyama K, Eto Y. Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the GLA gene. Mol Genet Metab Rep 2019; 20: 100497","journal-title":"Mol Genet Metab Rep"},{"issue":"14","key":"1131_CR36","doi-asserted-by":"publisher","first-page":"7663","DOI":"10.3390\/ijms22147663","volume":"22","author":"E Viggiano","year":"2021","unstructured":"Viggiano E, Politano L. X chromosome inactivation in carriers of Fabry disease: review and meta-analysis. Int J Mol Sci 2021; 22(14): 7663","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1131_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12882-023-03138-w","volume":"24","author":"W Guo","year":"2023","unstructured":"Guo W, Xie Y, Ji P, Li S, Cai G, Chen X. The evolution of the initial manifestations and renal involvement of chinese patients with classical and late-onset Fabry disease at different sexes and ages. BMC Nephrol 2023; 24(1): 90","journal-title":"BMC Nephrol"},{"issue":"6","key":"1131_CR38","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1074\/jbc.M109.060145","volume":"285","author":"AI Guce","year":"2010","unstructured":"Guce AI, Clark NE, Salgado EN, Ivanen DR, Kulminskaya AA, Brumer H III, Garman SC. Catalytic mechanism of human \u03b1-galactosidase. J Biol Chem 2010; 285(6): 3625\u20133632","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"1131_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1096-7192(02)00151-8","volume":"77","author":"SC Garman","year":"2002","unstructured":"Garman SC, Garboczi DN. Structural basis of Fabry disease. Mol Genet Metab 2002; 77(1\u20132): 3\u201311","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1131_CR40","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","volume":"114","author":"S Ferreira","year":"2015","unstructured":"Ferreira S, Ortiz A, Germain DP, Viana-Baptista M, Caldeira-Gomes A, Camprecios M, Fenollar-Cort\u00e9s M, Gallegos-Villalobos \u00c1, Garcia D, Garcia-Robles JA, Egido J, Guti\u00e9rrez-Rivas E, Herrero JA, Mas S, Oancea R, P\u00e9res P, Salazar-Martin LM, Solera-Garcia J, Alves H, Garman SC, Oliveira JP. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. Mol Genet Metab 2015; 114(2): 248\u2013258","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1131_CR41","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez ALD, Eng CM, Tanaka H, Tei C, Desnick RJ. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int 2003; 64(3): 801\u2013807","journal-title":"Kidney Int"},{"issue":"2","key":"1131_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","volume":"96","author":"DP Germain","year":"2019","unstructured":"Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M, Rivera S, Desch \u00eanes G, Lacombe D. Coessusus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet 2019; 96(2): 107\u2013117","journal-title":"Clin Genet"},{"issue":"3","key":"1131_CR43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34(3): 236\u2013242","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"1131_CR44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.gene.2012.06.013","volume":"505","author":"D Elstein","year":"2012","unstructured":"Elstein D, Schachamorov E, Beeri R, Altarescu G. X-inactivation in Fabry disease. Gene 2012; 505(2): 266\u2013268","journal-title":"Gene"},{"issue":"4","key":"1131_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00439-005-1300-5","volume":"117","author":"F Matsuzawa","year":"2005","unstructured":"Matsuzawa F, Aikawa S, Doi H, Okumiya T, Sakuraba H. Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes. Hum Genet 2005; 117(4): 317\u2013328","journal-title":"Hum Genet"},{"issue":"2","key":"1131_CR46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bbadis.2009.11.003","volume":"1802","author":"C Filoni","year":"2010","unstructured":"Filoni C, Caciotti A, Carraresi L, Cavicchi C, Parini R, Antuzzi D, Zampetti A, Feriozzi S, Poisetti P, Garman SC, Guerrini R, Zammarchi E, Donati MA, Morrone A. Functional studies of new GLA gene mutations leading to conformational Fabry disease. Biochim Biophys Acta Mol Basis Dis 2010; 1802(2): 247\u2013252","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"8","key":"1131_CR47","doi-asserted-by":"publisher","first-page":"e0161330","DOI":"10.1371\/journal.pone.0161330","volume":"11","author":"X Pan","year":"2016","unstructured":"Pan X, Ouyang Y, Wang Z, Ren H, Shen P, Wang W, Xu Y, Ni L, Yu X, Chen X, Zhang W, Yang L, Li X, Xu J, Chen N. Genotype: a crucial but not unique factor affecting the clinical phenotypes in Fabry disease. PLoS One 2016; 11(8): e0161330","journal-title":"PLoS One"},{"issue":"6","key":"1131_CR48","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/BF03402156","volume":"8","author":"DP Germain","year":"2002","unstructured":"Germain DP, Shabbeer J, Cotigny S, Desnick RJ. Fabry disease: twenty novel \u03b1-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes. Mol Med 2002; 8(6): 306\u2013312","journal-title":"Mol Med"},{"key":"1131_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","volume":"190","author":"BK Burton","year":"2017","unstructured":"Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR, Schneider M, Grange DK, Nash C, Shryock H, Barnett R, Shao R, Basheeruddin K, Dizikes G. Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr 2017; 190: 130\u2013135","journal-title":"J Pediatr"},{"issue":"5","key":"1131_CR50","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","volume":"2","author":"HY Lin","year":"2009","unstructured":"Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, Lin SJ, Chen CH, Chiang CC, Ho HJ, Lee PC, Kao CH, Cheng KH, Hsueh C, Niu DM. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Chinese Taiwan population. Circ Cardiovasc Genet 2009; 2(5): 450\u2013456","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"1131_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s10038-017-0366-y","volume":"63","author":"YH Lu","year":"2018","unstructured":"Lu YH, Huang PH, Wang LY, Hsu TR, Li HY, Lee PC, Hsieh YP, Hung SC, Wang YC, Chang SK, Lee YT, Ho PH, Ho HC, Niu DM. Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry. J Hum Genet 2018; 63(1): 1\u20138","journal-title":"J Hum Genet"},{"issue":"1","key":"1131_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1034\/j.1399-0004.2001.600107.x","volume":"60","author":"GM Altarescu","year":"2001","unstructured":"Altarescu GM, Goldfarb LG, Park KY, Kaneski C, Jeffries N, Litvak S, Nagle JW, Schiffmann R. Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 2001; 60(1): 46\u201351","journal-title":"Clin Genet"}],"container-title":["Frontiers of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-025-1131-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-025-1131-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-025-1131-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T08:04:48Z","timestamp":1749629088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-025-1131-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1007\/s11684-025-1131-9","relation":{},"ISSN":["2095-0217","2095-0225"],"issn-type":[{"value":"2095-0217","type":"print"},{"value":"2095-0225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of interest\n                      Wenkai Guo, Yuansheng Xie, Pengcheng Ji, Qinggang Li, Peng Wang, and Guangyan Cai have declared that no competing interest exists. Xiangmei Chen is a member of the Editorial Board of Frontiers of Medicine, who was excluded from the peer-review process and all editorial decisions related to the acceptance and publication of this article. Peer-review was handled independently by the other editors to minimise bias.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This clinical study was reviewed and approved by the Medical Ethics Committee of the Chinese PLA General Hospital (approval number: 2012-001), and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All participants provided written informed consent. For minors, parents\/legal guardians were informed, and their parents\/legal guardians signed the informed consent instead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}